Parkway Wealth Management Group LLC acquired a new stake in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 380,824 shares of the company’s stock, valued at approximately $24,754,000. SPDR S&P Pharmaceuticals ETF comprises about 2.8% of Parkway Wealth Management Group LLC’s portfolio, making the stock its 12th biggest holding. Parkway Wealth Management Group LLC owned 5.33% of SPDR S&P Pharmaceuticals ETF at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in XPH. Turtle Creek Wealth Advisors LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the first quarter worth $26,000. Rockefeller Capital Management L.P. increased its stake in shares of SPDR S&P Pharmaceuticals ETF by 3.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 20,043 shares of the company’s stock valued at $1,123,000 after purchasing an additional 627 shares during the last quarter. Western Wealth Management LLC bought a new position in shares of SPDR S&P Pharmaceuticals ETF in the 1st quarter valued at $34,000. Fifth Third Bancorp bought a new position in shares of SPDR S&P Pharmaceuticals ETF in the 1st quarter valued at $39,000. Finally, First Citizens Bank & Trust Co. raised its holdings in shares of SPDR S&P Pharmaceuticals ETF by 0.7% during the 1st quarter. First Citizens Bank & Trust Co. now owns 187,397 shares of the company’s stock worth $10,136,000 after buying an additional 1,393 shares in the last quarter.
SPDR S&P Pharmaceuticals ETF Stock Performance
SPDR S&P Pharmaceuticals ETF stock opened at $62.24 on Tuesday. SPDR S&P Pharmaceuticals ETF has a 52 week low of $47.60 and a 52 week high of $74.35. The stock has a market capitalization of $445.02 million, a P/E ratio of 14.28 and a beta of 0.61. The stock has a fifty day moving average of $67.89 and a 200-day moving average of $63.86.
SPDR S&P Pharmaceuticals ETF Company Profile
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
